ROSEN, A TOP-RANKED INVESTOR RIGHTS FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

Group 1 - The Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Capricor Therapeutics, Inc. securities between October 9, 2024, and July 10, 2025 [1] - Investors who purchased Capricor securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by September 15, 2025, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5] - The misleading statements led to shareholders purchasing Capricor's securities at artificially inflated prices, resulting in damages when the true information was revealed [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]